Faeth Therapeutics: Topline Results From the Phase 2 PIK-201 Trial in Endometrial Cancer Expected by Yr-end >FTH

What happened

Faeth Therapeutics reported a third-quarter 2026 net loss of $20.4 million, or $0.79 per share. It had $174.8 million in cash, cash equivalents and marketable securities on September 30. The company expects initial results from its Phase 2 endometrial cancer trial by year-end.

Global impact / market context

The reported cash and loss give investors a snapshot of the company’s finances, while the expected trial results are a future update on its cancer research. The supplied information does not show how the market reacted.

What to watch

1. Check whether the trial’s initial endometrial cancer results are reported by year-end, as the company expects.
2. Check the company’s next reported cash and securities total, to see how its available funds change.
3. Check the next reported net loss, to see how the company’s losses change.

Affected assets

• Faeth Therapeutics

Evidence

• Infoway News — Faeth Therapeutics Reports Q3 2026 Results, $174.8 Million in Cash and Securities 2026-11-03T13:25:32+00:00
• Infoway News — FTH: PIKTOR advances toward endometrial cancer data as Q3 net loss reaches $20.4 million 2026-11-03T13:15:01+00:00
• Infoway News — Faeth Therapeutics: Topline Results From the Phase 2 PIK-201 Trial in Endometrial Cancer Expected by Yr-end >FTH 2026-11-03T12:32:00+00:00
• Incident timeline — Faeth Therapeutics Reports Q3 2026 Results, $174.8 Million in Cash and Securities
• Incident timeline — FTH: PIKTOR advances toward endometrial cancer data as Q3 net loss reaches $20.4 million
• Incident timeline — Faeth Therapeutics: Topline Results From the Phase 2 PIK-201 Trial in Endometrial Cancer Expected by Yr-end >FTH